LUIS VINUELA: Open Payments
NPI 1710943311 · MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,067 in 52 payments from 13 companies in 2025. Trend: 2023 $1,503 · 2024 $1,213 · 2025 $1,067
Food & beverage: $1,067
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $292 |
| Alkermes, Inc. | 10 | $151 |
| E.R. Squibb & Sons, L.L.C. | 5 | $111 |
| Vanda Pharmaceuticals Inc. | 5 | $100 |
| ABBVIE INC. | 4 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Lundbeck LLC | 2 | $45 |
| Neurocrine BioSciences, Inc. | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 2 | $33 |
Products named: CAPLYTA, ARISTADA, COBENFY, FANAPT, VRAYLAR, TRINTELLIX, UZEDY, REXULTI.
Industry payments across FL — which companies pay providers there.
